Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Amifampridine for the Treatment of Transient Vocal Weakness After OnabotulinumtoxinA Injection for Spasmodic Dysphonia

NCT05123053 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT05123053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05123053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Amifampridine for the Treatment of Transient Vocal Weakness After OnabotulinumtoxinA Injection for Spasmodic Dysphonia
Lead sponsor
Augusta University
Phase
Phase 2
Overall status
Completed
Start date
October 28, 2021
Completion date
September 23, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vocal weakness(post-botox injection)